Cancer Family
Peritoneal Mesothelial Neoplasm
CI-CAN-00000317Explore in graph →
Non-malignant11 active trials2 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000317Explore in graph →
Clinical trials
27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06057935 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05001880 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials
| active not recruiting |
| Phase 2 |
| 133 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT01617382 | Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed(HIPEC) | recruiting | — | 125 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07330271 | PTC-Guided Therapy for Peritoneal Mesothelioma | recruiting | N/A | 347 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | recruiting | Phase 1 | 70 | Context Therapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | suspended | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03875144 | Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)(MESOTIP) | suspended | Phase 2 | 66 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03867578 | Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma | completed | N/A | 26 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05193006 | Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma | unknown | — | 300 | Hospices Civils de LyonOTHER | 6 | Jan 14, 2022 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02151448 | αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies | completed | Phase 1 / Phase 2 | 64 | David BartlettOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01160458 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02834169 | French National Registry of Rare Peritoneal Surface Malignancies(RENAPE) | unknown | — | 2,171 | Hospices Civils de LyonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02834234 | Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays | completed | — | 33 | Hospices Civils de LyonOTHER | 0 | Jul 26, 2016 | clinicaltrials |
| NCT02588131 | A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) | unknown | Phase 2 | 40 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Oct 27, 2015 | clinicaltrials |